{"nctId":"NCT02063659","briefTitle":"Telotristat Etiprate for Carcinoid Syndrome Therapy","startDateStruct":{"date":"2014-03-11","type":"ACTUAL"},"conditions":["Carcinoid Syndrome"],"count":76,"armGroups":[{"label":"250 mg Telotristat Etiprate","type":"EXPERIMENTAL","interventionNames":["Drug: Telotristat etiprate","Drug: Placebo"]},{"label":"500 mg Telotristat Etiprate","type":"EXPERIMENTAL","interventionNames":["Drug: Telotristat etiprate","Drug: Placebo"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Telotristat etiprate","otherNames":["LX1606"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients ≥ 18 years of age\n* All patients of reproductive potential must agree to use an adequate method of contraception during the study and for 12 weeks after the Follow-up visit.\n* Histopathologically-confirmed, well-differentiated metastatic neuroendocrine tumor\n* Documented history of carcinoid syndrome\n* Patient is able and willing to provide written informed consent prior to participation\n\nExclusion Criteria:\n\n* Presence of diarrhea attributed to any condition other than carcinoid syndrome.\n* Presence of 12 or more watery bowel movements per day\n* Positive stool examination for enteric pathogens, pathogenic ova or parasites, of Clostridium difficile at Screening\n* Karnofsky Performance Status ≤ 60%\n* Presence of any clinically significant laboratory, medical history, or physical examination findings deemed unacceptable by the Investigator\n* A history of short bowel syndrome\n* History of constipation within 2 years of Screening\n* Life expectancy \\< 12 months from Screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Treatment Period","description":"An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A TEAE was an AE reported after the first dose of randomized treatment on Day 1.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]}]},{"type":"PRIMARY","title":"Primary: Percent Change From Baseline in Urinary 5-hydroxyindoleacetic Acid (u5-HIAA) Levels","description":"u5-HIAA is a standard test used in clinical practice to assess neuroendocrine tumor (NET) activity and is collected as a 24-hour urine specimen. A negative change from Baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.721","spread":"397.0107"},{"groupId":"OG001","value":"-33.164","spread":"58.4754"},{"groupId":"OG002","value":"-76.466","spread":"17.3714"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Open-Label Extension Period","description":"An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A TEAE was an AE reported after the first dose of randomized treatment on Day 1.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Number of Bowel Movements (BMs) Per Day Averaged Over 12 Weeks","description":"Participants recorded the number of bowel movements per day in a daily diary. The total number of BMs per day were averaged over the 12-week period. A negative change from Baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.050","spread":"0.3263"},{"groupId":"OG001","value":"-0.452","spread":"0.6940"},{"groupId":"OG002","value":"-0.595","spread":"0.7240"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Stool Form/Consistency Averaged Across All Time-Points","description":"Participants assessed stool form/consistency of a BM using the Bristol Stool Form Scale where: 1=hard lumps to 7=watery liquid. The daily scores were averaged over the 12-week period. A negative change indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.006","spread":"0.4127"},{"groupId":"OG001","value":"-0.196","spread":"0.7012"},{"groupId":"OG002","value":"-0.597","spread":"0.8605"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Number of Daily Cutaneous Flushing Episodes Averaged Across All Time-Points","description":"Participants recorded the number daily flushing episodes per day in a daily diary. The total number of flushing episodes per day were averaged over the 12-week period. A negative change from Baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.333","spread":"1.2203"},{"groupId":"OG001","value":"-0.061","spread":"0.9754"},{"groupId":"OG002","value":"0.114","spread":"2.0992"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Abdominal Pain Averaged Across All Time-Points","description":"Participants recorded abdominal pain in a daily diary. Participants evaluated the level of any abdominal pain using an 11-point numeric rating scale, where: 0=no pain to 10=worst pain ever experienced. The average daily abdominal pain was averaged over the 12-week period. A negative change from Baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.063","spread":"0.7823"},{"groupId":"OG001","value":"-0.234","spread":"0.9697"},{"groupId":"OG002","value":"0.025","spread":"0.7744"}]}]}]},{"type":"SECONDARY","title":"Change in the Frequency of Rescue Short-acting, Somatostatin Analog (SSA) Used to Treat Carcinoid Syndrome Symptoms Averaged Across All Time-Points","description":"The frequency (the number of times) the participant used rescue with SSA to control symptoms was recorded in a daily diary. The daily number of rescue treatments with SSA was averaged over the 12- week period. A negative change from Baseline (less use of SSA) indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.013","spread":"0.1359"},{"groupId":"OG001","value":"-0.065","spread":"0.3542"},{"groupId":"OG002","value":"0.006","spread":"0.1030"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Number of Daily BMs Averaged Over the 12-Week Double-Blind Period, Among Participants Who Were Not Receiving SSA Therapy at Baseline","description":"Participants recorded the number of bowel movements per day in a daily diary. The total number of BMs per day were averaged over the 12-week period. A negative change from Baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.906","spread":"0.5925"},{"groupId":"OG001","value":"-0.98","spread":"1.154"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":26},"commonTop":["Abdominal pain","Nausea","Diarrhoea","Constipation","Fatigue"]}}}